- Home
- DCTH vs SPXX Comparison
DCTH vs SPXX Comparison
Compare DCTH & SPXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- SPXX
- Stock Information
- Founded
- DCTH 1988
- SPXX 2004
- Country
- DCTH United States
- SPXX United States
- Employees
- DCTH N/A
- SPXX N/A
- Industry
- DCTH Medical/Dental Instruments
- SPXX Trusts Except Educational Religious and Charitable
- Sector
- DCTH Health Care
- SPXX Finance
- Exchange
- DCTH Nasdaq
- SPXX Nasdaq
- Market Cap
- DCTH 630.4M
- SPXX 305.0M
- IPO Year
- DCTH N/A
- SPXX N/A
- Fundamental
- Price
- DCTH $13.57
- SPXX $17.68
- Analyst Decision
- DCTH Strong Buy
- SPXX
- Analyst Count
- DCTH 4
- SPXX 0
- Target Price
- DCTH $24.00
- SPXX N/A
- AVG Volume (30 Days)
- DCTH 734.6K
- SPXX 51.3K
- Earning Date
- DCTH 08-04-2025
- SPXX 01-01-0001
- Dividend Yield
- DCTH N/A
- SPXX 7.55%
- EPS Growth
- DCTH N/A
- SPXX N/A
- EPS
- DCTH N/A
- SPXX N/A
- Revenue
- DCTH $53,850,000.00
- SPXX N/A
- Revenue This Year
- DCTH $155.42
- SPXX N/A
- Revenue Next Year
- DCTH $37.93
- SPXX N/A
- P/E Ratio
- DCTH N/A
- SPXX N/A
- Revenue Growth
- DCTH 1068.87
- SPXX N/A
- 52 Week Low
- DCTH $7.17
- SPXX $13.57
- 52 Week High
- DCTH $18.23
- SPXX $16.05
- Technical
- Relative Strength Index (RSI)
- DCTH 38.26
- SPXX 60.38
- Support Level
- DCTH $12.98
- SPXX $16.80
- Resistance Level
- DCTH $14.18
- SPXX $17.12
- Average True Range (ATR)
- DCTH 0.68
- SPXX 0.18
- MACD
- DCTH -0.28
- SPXX 0.00
- Stochastic Oscillator
- DCTH 15.95
- SPXX 84.52
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
About SPXX Nuveen S&P 500 Dynamic Overwrite Fund
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on approximately 35%-75% of the notional value of the Fund's equity portfolio in an effort to enhance the Fund's risk-adjusted returns.